ONCS - OncoSec Medical Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2150
+0.0050 (+0.23%)
As of 1:16PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.2100
Open2.2300
Bid2.2100 x 3000
Ask2.2300 x 800
Day's Range2.1150 - 2.2800
52 Week Range1.8000 - 19.6000
Volume54,341
Avg. Volume102,243
Market Cap23.516M
Beta (3Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-5.9310
Earnings DateDec 6, 2017 - Dec 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference
    PR Newswire

    OncoSec to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    SAN DIEGO and PENNINGTON, N.J. , Sept. 6, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced ...

  • PR Newswire

    OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

    SAN DIEGO and PENNINGTON, N.J., July 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915. The allowed patent application covers methods of treating a patient having treatment-refractory, cutaneous or subcutaneous, cancerous tumors, that involve injecting the tumor with a plasmid coding for an immunostimulatory cytokine (e.g. "The claims granted by the USPTO provide OncoSec with broad-based protection on the very valuable combination of intratumoral cytokines, electroporation and checkpoint inhibitor therapy.  We continue to fortify the patent portfolio around our technology, which employs electroporation and local cytokine delivery and continues to demonstrate impressive systemic tumor responses, particularly when combined with checkpoint inhibitors," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.

  • OncoSec Issues Letter to Shareholders
    PR Newswire

    OncoSec Issues Letter to Shareholders

    SAN DIEGO and PENNINGTON, N.J , July 16, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today published ...

  • OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
    PR Newswire

    OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

    SAN DIEGO and PENNINGTON, N.J., June 27, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute, a world-leading cancer research and treatment institution, and The Marasco Laboratory, a cutting-edge CAR T-cell research laboratory led by Wayne Marasco, M.D., Ph.D., a renowned cancer immunology researcher, to develop CAR T-cell therapies for triple-negative breast cancer and other solid tumor cancers.

  • OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator
    PR Newswire

    OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO™ Electroporation Generator

    IVM is a powerful tool enabling real-time in vivo visualization of important immune activation and movements in tumor microenvironment driven by TAVO-PLUS SAN DIEGO , and PENNINGTON, N.J. , June 17, 2019 ...

  • OncoSec to Present Immunological Data at World Pharma Week 2019
    PR Newswire

    OncoSec to Present Immunological Data at World Pharma Week 2019

    Compelling Data from Multiple Clinical Trials Using Company's Biomarker Technology Support Novel Approach to Immune Resistance Mechanisms in Cancer SAN DIEGO and PENNINGTON, N.J. , June 13, 2019 /PRNewswire/ ...

  • Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix
    Zacks

    Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

    Zacks.com featured highlights include: HP, Party City, AbbVie, OncoSec Medical and Pulmatrix

  • Bet on 5 Top Stocks With Rising P/E
    Zacks

    Bet on 5 Top Stocks With Rising P/E

    Bet on these top-ranked stocks with rising P/E to realize outsized gains.

  • OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health
    PR Newswire

    OncoSec Announces Collaboration For TAVO™ In Australia With Emerge Health

    TAVO to Become Revenue Generating Potentially As Early As Year-End 2019 Collaboration uses Australia's Special Access Scheme (SAS) Allowing Patients Prescription Access To TAVO at Commercial Rates Prior ...

  • OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility
    PR Newswire

    OncoSec Medical Incorporated Announces Closing of $11.0 Million Public Offering and Terminates ATM and Other Financing Facility

    SAN DIEGO and PENNINGTON, N.J., May 28, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a biotechnology company focused on designing, developing and commercializing innovative immunotherapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer, today announced the closing of its previously announced underwritten public offering. The gross proceeds from the offering were approximately $11 million, before deducting underwriting discounts and commissions and estimated offering expenses paid by OncoSec. Alliance Global Partners acted as lead book-running manager for the offering.  Maxim Group LLC acted as co-manager and Roth Capital Partners, LLC and ThinkEquity, a division of Fordham Financial Management, Inc., acted as financial advisors for this offering.

  • Benzinga

    Secondary Offerings Put A Pause On May's Momentum

    During Thursday’s recap, I touched on why I think an excess of secondary offerings might be part of the reason for the faltering momentum. Four of the stocks I traded in the week, Can Fite Biopharma ADR (NYSE: CANF), Obalon Therapeutics Inc. (NASDAQ: OBLN), MYnd Analytics Inc. (NASDAQ: MYND) and OncoSec Medical Inc. (NASDAQ: ONCS) each announced a secondary offering. The net effect of these offerings is more share supply, less demand and a growing reticence amongst traders to buy into cheaper stocks like CANF and OBLN for fear of getting caught in a news halt and losing their shirts.

  • UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer
    PR Newswire

    UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

    First-of-its-kind study seeking to evaluate the potential anti-tumor effect of the IL-12, IDO1 and anti-PD-1 triple combination SAN DIEGO and PENNINGTON, N.J. , May 23, 2019 /PRNewswire/ -- OncoSec Medical ...

  • OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session
    Zacks

    OncoSec Medical (ONCS) Looks Good: Stock Adds 6.6% in Session

    OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • OncoSec Medical Incorporated Prices $11,000,000 Public Offering
    PR Newswire

    OncoSec Medical Incorporated Prices $11,000,000 Public Offering

    SAN DIEGO and PENNINGTON, N.J., May 22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced the pricing of an underwritten public offering led by fundamental, healthcare institutional investors consisting of 3,492,063 shares of Common Stock together with Warrants to purchase up to 2,619,047 shares of Common Stock at a combined price to the public of $3.15. OncoSec has granted the underwriter a 45-day option to purchase additional shares of Common Stock and/or additional Warrants to cover over-allotments, if any. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-213036) previously filed with the U.S. Securities and Exchange Commission (the "SEC").

  • OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer
    PR Newswire

    OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

    50% of Evaluated Patients Experienced a 20% or Greater Tumor Reduction SAN DIEGO and PENNINGTON, N.J. , May 22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage cancer ...

  • Why These Stocks Are On The Move
    Insider Monkey

    Why These Stocks Are On The Move

    It's Wednesday morning and traders are talking about the potential for the Fed to cuts rates if inflation dissapoints and also the AmCham China chairman Tim Stratford's comments that some of its members are worried about China's response to the U.S. adding Huawei to its 'entity list', which hurts the tech company's ability to do various […]

  • OncoSec Medical Incorporated Announces Proposed Public Offering
    PR Newswire

    OncoSec Medical Incorporated Announces Proposed Public Offering

    SAN DIEGO and PENNINGTON, N.J., May 21, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that it intends to offer for sale a combination of shares of its common stock and warrants in an underwritten public offering. This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-213036) previously filed with the U.S. Securities and Exchange Commission (the "SEC").

  • OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries
    PR Newswire

    OncoSec Granted Exclusive Worldwide Rights To A Patent Portfolio For The Combination Use Of IL-12 DNA With Checkpoint Inhibitors To Treat Cancer In Several Key Countries

    IL-12 has emerged as an important pro-inflammatory signaling cytokine, which many other companies are now using to develop cancer immunotherapies with several different modalities.  The exclusive rights OncoSec has secured in this patent portfolio cover the use of IL-12 DNA, in combination with checkpoint inhibitors, while pending applications are pursuing broader claims, across multiple jurisdictions. "IL-12's ability to turn cold tumors hot has immense potential to transform the outcomes of the large number of patients whose disease does not respond to monotherapy with checkpoint blockade.  We are delighted to partner with OncoSec, leaders in the DNA-based delivery of IL-12, and look forward to the results of ongoing trials, and to the anticipated approval of TAVO™ in combination with KEYTRUDA®," said Professor Burkhard Becher, Director of the Institute of Experimental Immunology at the University of Zurich.

  • OncoSec Announces 1-for-10 Reverse Stock Split
    PR Newswire

    OncoSec Announces 1-for-10 Reverse Stock Split

    SAN DIEGO and PENNINGTON, N.J., May 20, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery immunotherapies, today announced that its Board of Directors has approved a one-for-ten (1-for-10) reverse stock split of its common stock.  The reverse stock split will become effective at 5:00 pm Eastern Time on May 20, 2019, and the Company's shares of common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on May 21, 2019 under the Company's existing symbol "ONCS."  The Company's common stock has been assigned a new CUSIP number of 68234L306 in connection with the reverse stock split. As a result of the reverse stock split, every 10 shares of common stock issued and outstanding were consolidated into one issued and outstanding share.  The reverse stock split reduced the Company's issued and outstanding shares of common stock from approximately 70 million to approximately 7 million.  In addition, proportionate adjustments will be made to the exercise prices of the Company's outstanding stock options and warrants and to the number of shares issued and issuable under the Company's existing stock incentive plans.

  • OncoSec to Present at ThinkEquity Conference 2019
    PR Newswire

    OncoSec to Present at ThinkEquity Conference 2019

    SAN DIEGO and PENNINGTON, N.J. , April 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced ...

  • If You Had Bought OncoSec Medical (NASDAQ:ONCS) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today
    Simply Wall St.

    If You Had Bought OncoSec Medical (NASDAQ:ONCS) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Imagine if you held OncoSec Medical Incorporated (NASDAQ:ON...

  • OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to it's Board of Directors
    PR Newswire

    OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to it's Board of Directors

    SAN DIEGO and PENNINGTON, N.J. , April 24, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment ...

  • OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer
    PR Newswire

    OncoSec Announces Triple Combination Immunotherapy Clinical Trial Of TAVO™, Epacadostat And KEYTRUDA® In Squamous Cell Head And Neck (SCCHN) Cancer

    -- Triple combination seeks to improve upon the low historical anti-PD1 monotherapy durable remissions response rate of 13-16% SAN DIEGO and PENNINGTON, N.J. , April 23, 2019 /PRNewswire/ -- OncoSec Medical ...

  • OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center
    PR Newswire

    OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO™ in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center

    Program Will Use OncoSec's New Apollo Generator to Evaluate TAVO™ in Combination with Plasmid DNA Vaccines for HER2+ Breast Cancers SAN DIEGO and PENNINGTON, N.J. , April 17, 2019 /PRNewswire/ -- OncoSec ...

  • OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
    PR Newswire

    OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12

    Company Published White Paper titled, "Parachuting Behind Enemy Lines: OncoSec's Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)" White Paper Unveils Ability to Directly ...